🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Effect of Acetylcysteine Inhalation on Incidence and Time to Develop Ventilator Associated Pneumonia in Critically Ill Mechanically Ventilated Patients

RecruitingPhase 4Ages 18 Years - 64 YearsAllCairo University
NCT07409727 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Background Mechanical ventilation is an essential medical intervention in the context of critical illness. However, the intervention is associated with a risk of significant, potentially preventable complications. Among these are ventilator-associated pneumonia, sepsis, acute respiratory distress syndrome, atelectasis, and pulmonary edema. Ventilator-associated complications commonly increase morbidity and mortality. They may also prolong the duration of mechanical ventilation and the length of stay in the hospital or the intensive care unit, with increased health care costs; so safe, effective therapeutic and preventative strategies are essential to attenuate poor outcomes from ventilator-associated events. Secretion retention and ineffective cough play a significant role in failed extubation and weaning from ventilator; the presence of the artificial airway, poor humidification of in

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Aged 18-64 years, either male or female. 2. Critically ill patients who have undergone intubation and are on mechanical ventilation. 3. Expected duration of mechanical ventilation of more than 48 hours. 4. Provided consent to participate in this clinical trial by next of kin. Exclusion Criteria: 1. Patients currently on long-term NAC treatment. 2. Confirmed brain death. 3. Recent chest infection. 4. Immunocompromised patients on immunosuppressive medication. 5. Patients mechanically ventilated in another hospital. 6. Pregnant women. 7. Mean arterial pressure (MAP) \<60 mmHg despite adequate resuscitation and vasopressor therapy at the time of randomization. 8. Known intolerance or hypersensitivity to study medication. 9. Presence of a condition or abnormality that would compromise the quality of the data. \-
💊

What it tests

  • Acetyl cysteine
  • Normal (0.9%) saline
📍

Where

1 site
Cairo University Hospitals
Cairo, Egypt
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy